Savara Inc. (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have received an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.1429.

SVRA has been the topic of several recent analyst reports. William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th.

Institutional Investors Weigh In On Savara

Several large investors have recently modified their holdings of SVRA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Savara in the 1st quarter valued at approximately $57,000. Russell Investments Group Ltd. increased its stake in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Xponance LLC bought a new stake in Savara during the 4th quarter worth approximately $66,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Savara during the 3rd quarter worth approximately $44,000. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Shares of Savara stock opened at $6.22 on Friday. The business has a fifty day simple moving average of $5.32 and a 200 day simple moving average of $5.56. The stock has a market cap of $1.27 billion, a PE ratio of -11.11 and a beta of 0.24. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara has a 12 month low of $2.10 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts predict that Savara will post -0.57 EPS for the current year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.